SPRY
ARS Pharmaceuticals, Inc. NASDAQ$8.56
Mkt Cap $843.7M
52w Low $6.66
15.5% of range
52w High $18.90
50d MA $8.46
200d MA $10.67
P/E (TTM)
-4.9x
EV/EBITDA
-6.8x
P/B
7.4x
Debt/Equity
0.8x
ROE
-149.9%
P/FCF
-6.7x
RSI (14)
—
ATR (14)
—
Beta
0.93
50d MA
$8.46
200d MA
$10.67
Avg Volume
1.4M
About
ARS Pharmaceuticals, Inc. develops ARS-1, a novel intranasal epinephrine spray with absorption technology for patients and their families at-risk of severe allergic reactions to food, medications, and insect bites. Its product includes Neffy, a low-dose intranasal epinephrine nasal spray. The company was incorporated in 2015 and is based in San Diego, California.
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | 1M% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 9, 2026 | AMC | -0.42 | -0.42 | +0.0% | 9.05 | +0.6% | -2.1% | -7.4% | -9.0% | -7.3% | -3.9% | -9.5% | — |
| Nov 10, 2025 | AMC | -0.45 | -0.52 | -15.6% | 8.88 | -1.7% | -1.2% | +0.8% | -5.3% | -7.5% | -17.6% | +17.6% | — |
| Aug 13, 2025 | AMC | -0.41 | -0.46 | -12.2% | 15.82 | -0.9% | -8.5% | -8.2% | -11.3% | -12.8% | -7.7% | -36.6% | — |
| May 14, 2025 | AMC | -0.35 | -0.35 | +0.0% | 12.10 | +0.5% | +0.8% | +12.4% | +17.9% | +18.4% | +17.5% | +27.2% | — |
| Mar 20, 2025 | AMC | -0.04 | 0.52 | +1400.0% | 14.31 | -0.4% | -13.6% | -9.9% | -8.1% | -11.9% | -11.7% | +0.1% | — |
| Nov 13, 2024 | AMC | -0.18 | -0.20 | -11.1% | 14.08 | +3.1% | +0.2% | -0.5% | -2.1% | -2.1% | -3.8% | -15.5% | — |
| Aug 6, 2024 | AMC | -0.12 | -0.13 | -8.3% | 9.78 | -1.0% | -2.1% | +1.1% | +11.2% | +10.9% | +33.5% | +20.1% | — |
| May 9, 2024 | AMC | -0.11 | -0.11 | +0.0% | 8.80 | +1.5% | -0.7% | +1.0% | +2.0% | +0.9% | +3.4% | +3.1% | — |
| Mar 21, 2024 | AMC | -0.14 | -0.07 | +50.0% | 9.00 | +0.0% | -3.9% | +1.4% | +11.1% | +10.7% | +13.6% | -8.8% | — |
| Nov 9, 2023 | AMC | -0.18 | -0.16 | +11.1% | 3.43 | +4.4% | +8.7% | +16.6% | +23.3% | +32.1% | +31.5% | +49.6% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jan 14 | Raymond James | Maintains | Strong Buy → Strong Buy | — | $11.26 | $11.91 | +5.8% | +0.9% | +6.7% | +8.2% | +11.6% | +19.7% |
| Jan 13 | Leerink Partners | Maintains | Outperform → Outperform | — | $11.24 | $11.40 | +1.4% | +0.2% | +1.1% | +6.9% | +8.4% | +11.8% |
| Oct 8 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $13.66 | $13.70 | +0.3% | +1.6% | +0.4% | +1.8% | +6.3% | +9.4% |
| Sep 20 | Leerink Partners | Maintains | Outperform → Outperform | — | $14.86 | $14.97 | +0.7% | -0.6% | -5.2% | -7.9% | -5.5% | -2.4% |
| Sep 16 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $13.30 | $13.43 | +1.0% | -2.6% | -1.9% | +5.6% | +11.7% | +11.1% |
| Sep 9 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $11.36 | $11.49 | +1.1% | +3.1% | +1.3% | +5.6% | +11.2% | +17.1% |
| Aug 13 | Raymond James | Upgrade | Outperform → Strong Buy | — | $10.85 | $12.00 | +10.6% | +20.4% | +19.8% | +24.8% | +22.9% | +31.2% |
| Mar 11 | Wedbush | Maintains | Outperform → Outperform | — | $8.69 | $8.59 | -1.2% | -4.6% | -2.6% | +3.6% | +3.6% | +5.4% |
| Mar 5 | Leerink Partners | Upgrade | Market Perform → Outperform | — | $8.65 | $9.32 | +7.7% | +2.7% | +3.1% | +3.5% | +0.5% | -4.2% |
| Nov 13 | Wedbush | Maintains | Outperform → Outperform | — | $3.73 | $3.90 | +4.6% | +7.2% | +13.4% | +21.4% | +20.9% | +26.3% |
Recent Filings
Data updated apr 27, 2026 2:40am
· Source: massive.com